[Guillain-Barré syndrome in hospitals in Togo].
Syndrome de Guillain-Barré en milieu hospitalier au Togo.
Epidemiology
Guillain-Barré syndrome
Hospital
Lomé
Prognosis
Sub-Saharan Africa
Togo
Journal
Medecine tropicale et sante internationale
ISSN: 2778-2034
Titre abrégé: Med Trop Sante Int
Pays: France
ID NLM: 9918227363206676
Informations de publication
Date de publication:
30 09 2021
30 09 2021
Historique:
received:
08
12
2020
accepted:
19
08
2021
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
14
6
2022
Statut:
epublish
Résumé
In sub-Saharan Africa characterized by limited resources especially in health facilities and a relatively higher frequency of infectious diseases, studies on Guillain-Barré syndrome (GBS) are rare. The objectives of this work are to describe the characteristics of GBS in Togo through a cohort of patients followed in the neurology unit of the Campus University Hospital of Lomé. The study took place from May 2015 to July 2019. Patients with GBS of levels 1 to 3 of the Brighton criteria for diagnostic certainty were included consecutively and assessed at admission, at 6 months and at 1 year with the GBS disability score and the MRC sum score. Qualitative and quantitative variables were expressed, respectively, in frequency and median (interquartile range). Out of 7012 hospitalized patients, 28 (0.39%) including 20 women (71%) with a median age of 40 (27-53) years, presented GBS. The clinical presentation mainly consisted of bilateral sensory-motor disorders predominantly in the lower limbs associated with facial diplegia and preceded by an infectious event. On admission, 39% of patients (n=11) were able to walk (GBS score 0 to 3) and the median MRC sum score was 28 (12-38). Cytoalbuminologic dissociation was present in 654% of patients (13 of 20 patients who underwent lumbar puncture). The demyelinating and axonal subtypes each accounted for 47% (9 of 19 patients who underwent an electroneuromyography examination). Immunoglobulins and intravenous corticosteroid therapy were administered in 18% (n=5) and 50% (n=14) of patients, respectively. Lethality rate during hospitalization was 11% (n=3). The median MRC sum score at 6 and 12 month-outcome were 40 (38-49) and 51 (46-58), respectively. After one year of evolution, case fatality rate was 18% (n=5), and 78% of survivors (n=14) could walk without assistance, of which 17% (n=3) were asymptomatic. In Togo, GBS, with a low hospital prevalence, remains a serious condition due to its high morbidity and lethality related to non-optimal treatment and delayed management.
Identifiants
pubmed: 35686169
doi: 10.48327/mtsibulletin.2021.124
pmc: PMC9128467
pii:
doi:
Types de publication
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2021 SFMTSI.
Déclaration de conflit d'intérêts
Les auteurs ne déclarent aucun conflit d'intérêt.
Références
Trends Immunol. 2013 Sep;34(9):453-9
pubmed: 23770405
Muscle Nerve. 1991 Nov;14(11):1103-9
pubmed: 1745285
Muscle Nerve. 2002 Mar;25(3):468
pubmed: 11870731
Cochrane Database Syst Rev. 2015 Apr 09;(4):CD009950
pubmed: 25855461
Brain. 2018 Oct 1;141(10):2866-2877
pubmed: 30247567
Lancet Neurol. 2007 Jul;6(7):589-94
pubmed: 17537676
J Neurol. 1988 Sep;235(7):418-21
pubmed: 3065464
Lancet. 2005 Nov 5;366(9497):1653-66
pubmed: 16271648
Rev Neurol (Paris). 2004 Sep;160(8-9):821-3
pubmed: 15454869
Neuroepidemiology. 2009;32(2):150-63
pubmed: 19088488
Front Neurol. 2019 Jul 02;10:714
pubmed: 31333568
J Neurol Neurosurg Psychiatry. 1973 Jun;36(3):478-83
pubmed: 4714110
Cochrane Database Syst Rev. 2014 Sep 19;(9):CD002063
pubmed: 25238327
Brain. 2014 Jan;137(Pt 1):33-43
pubmed: 24163275